Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.625 USD | -2.60% | +1.46% | +9.65% |
Jun. 12 | XOMA Receives $8.1 Million Milestone Related to Sale of Priority Review Voucher | MT |
May. 30 | Day One Biopharmaceuticals Sells Priority Review Voucher for $108 Million | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.65% | 25.2M | |
+41.95% | 55.66B | |
-8.81% | 38.98B | |
+35.43% | 38.8B | |
-9.38% | 27.32B | |
+9.97% | 26.29B | |
-15.82% | 20.25B | |
+30.23% | 12.76B | |
+26.86% | 12.18B | |
-1.54% | 12.12B |
- Stock Market
- Equities
- VIRX Stock
- News Viracta Therapeutics, Inc.
- Viracta Therapeutics Initiated at Outperform by RBC With Speculative Risk Qualifier, Price Target Started at $10/Share